%0 Journal Article
%T Ustekinumab Treatment in Patients with Moderate-to-Severe Psoriasis and Latent Tuberculosis Infection: A Study of 3 Case Reports
%A Waqas S. Abdulwahhab
%A Alaa S. Mehair
%A Al Shayma F. Iedi
%J Journal of Cosmetics, Dermatological Sciences and Applications
%P 95-99
%@ 2161-4512
%D 2022
%I Scientific Research Publishing
%R 10.4236/jcdsa.2022.122008
%X <strong>Background:</strong> Ustekinumab is a human monoclonal antibody that binds to the shared P40 subunit of interleukin (IL)-12 and IL-23 and is approved for the treatment of moderate-to-severe psoriasis. Latent tuberculosis (LTBI) was diagnosed based on a positive tuberculin skin test (TST) or QuantiFERON-TB test without evidence of active tuberculosis (TB). <strong>Aim:</strong> To evaluate the risk of active tuberculosis reinfection in patients with a history of psoriasis and LTBI after INH prophylaxis treated with Ustekinumab. <strong>Case Report:</strong> We are describing 3 patients with a history of moderate-to-severe plaque psoriasis and newly identified LTBI who have been treated with INH monotherapy before starting Ustekinumab therapy followed-up over 2 years for any sign of tuberculosis reinfection. <strong>Conclusion:</strong> Ustekinumab is an option for treating psoriasis and LTBI with minimal risk of reactivation after INH prophylaxis.
%K Psoriasis
%K Ustekinumab
%K Latent Tuberculosis
%K QuantiFERON-TB Test
%U http://www.scirp.org/journal/PaperInformation.aspx?PaperID=117909